Drug class
Lactate dehydrogenase A (LDHA)-directed small interfering RNA (siRNA); RNA interference therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of LDHA mRNA, reducing hepatic glycolate-to-glyoxylate conversion and lowering oxalate production.
General use cases
- Reduction of urinary oxalate in adults and children aged 2 years and older with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function (eGFR at least 30 mL/min/1.73 m²) under the US RIVFLOZA indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
